Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.

Jing ZhengTao WangYunpeng YangJie HuangJifeng FengWu ZhuangJianhua ChenJun ZhaoWei ZhongYanqiu ZhaoYiping ZhangYong SongYi HuZhuang YuYouling GongYuan ChenFeng YeShucai ZhangLejie CaoYun FanGang WuYubiao GuoChengzhi ZhouKewei Ma Jian FangWeineng FengYunpeng LiuZhendong ZhengGaofeng LiHuijie WangShundong CangNing WuWei SongXiaoqing LiuShijun ZhaoLieming DingGiovanni SelvaggiYang WangShanshan XiaoQian WangZhilin ShenJianya ZhouJianying ZhouLi Zhang

Published in: Cancer communications (London, England) (2024)

Ensartinib led to a favorable OS in patients with advanced, crizotinib-resistant, and ALK-positive NSCLC. Quantification of ctDNA levels also provided valuable prognostic information for risk stratification.

Keyphrases

circulating tumor
advanced non small cell lung cancer
phase ii study
epidermal growth factor receptor
cell free
circulating tumor cells
open label
locally advanced
small cell lung cancer
tyrosine kinase
healthcare
randomized controlled trial
radiation therapy
rectal cancer
brain metastases
nucleic acid